enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Zepbound Weight Loss Medication Approved by FDA to Treat ...

   www.aol.com/fda-approves-weight-loss-medication...

   The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release. The ...

3. Daridorexant - Wikipedia

   en.wikipedia.org/wiki/Daridorexant

   Daridorexant is indicated for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. [1] The medication has been found to significantly improve latency to persistent sleep (LPS), wake after sleep onset (WASO), and subjective total sleep time (TST) in regulatory clinical trials. [1]

4. Lemborexant - Wikipedia

   en.wikipedia.org/wiki/Lemborexant

   Lemborexant is used in the treatment of insomnia in adults. [3]A major systematic review and network meta-analysis of medications for the treatment of insomnia published in 2022 found that lemborexant had an effect size (standardized mean difference (SMD)) against placebo for treatment of insomnia at 4 weeks of 0.36 (95% CI Tooltip confidence interval 0.08 to 0.63) and at 3 months of 0.41 (95% ...

5. List of investigational sleep drugs - Wikipedia

   en.wikipedia.org/wiki/List_of_investigational...

   This is a list of investigational sleep drugs, or drugs for the treatment of sleep disorders that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

6. Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults ...

   lite.aol.com/tech/story/0022/20241218/1001029573.htm

   Insomnia: Dosage regimen: The usual adult dosage is 50 mg of daridorexant to be taken orally once daily immediately before bedtime. In addition, depending on the patient's condition, 25 mg can be administered once daily. Date of approval: 24 September 2024: Date of NHI price listing: 20 November 2024: Date of launch: 19 December 2024: Drug price

7. Why the FDA Rejected This New Insomnia Drug - AOL

   www.aol.com/news/2013-07-01-why-the-fda-rejected...

   Shares of Merck closed flat as the market digests the FDA rejection of new insomnia drug suvorexant. ... health-care analyst David Williamson discusses why the FDA is holding up approval for this ...